Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gareth Beevers

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
International Journal of Cardiology|December 24, 2011
A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: the West Birmingham Malignant Hypertension projectAlena Shantsila, Girish Dwivedi, Eduard Shantsila, et al.
Hypertension (Dallas, Tex. : 1979)|January 26, 2011
Persistent macrovascular and microvascular dysfunction in patients with malignant hypertensionAlena Shantsila, Girish Dwivedi, Eduard Shantsila, et al.
American Journal of Hypertension|September 20, 2008
Hypertension due to a renin-secreting juxtaglomerular cell tumorD Gareth Beevers, Madhavi B Maheshwari, Peter G Ryan, et al.
Journal of the American College of Cardiology|July 21, 2004
Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Sunil K Nadar, Andrew D Blann, Sridhar Kamath, et al.
Hypertension (Dallas, Tex. : 1979)|July 10, 2002
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Charles G C Spencer, David Gurney, Andrew D Blann, et al.
Hypertension (Dallas, Tex. : 1979)|March 8, 2003
Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatmentDirk C Felmeden, Charles G C Spencer, Andrew D Blann, et al.
Chest|November 14, 2007
Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in hypertensionChristopher J Boos, Deirdre A Lane, Manas Karpha, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 12, 2011
Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factorV J Karthikeyan, Andrew D Blann, Sabah Baghdadi, et al.
Journal of Hypertension|December 2, 2010
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnanciesVellore J Karthikeyan, Robin E Ferner, Sabah Baghdadi, et al.
American Journal of Hypertension|September 15, 2004
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Muzahir H Tayebjee, Sunil Nadar, Andrew D Blann, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
International Journal of Cardiology|December 24, 2011
A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: the West Birmingham Malignant Hypertension projectAlena Shantsila, Girish Dwivedi, Eduard Shantsila, et al.
Hypertension (Dallas, Tex. : 1979)|January 26, 2011
Persistent macrovascular and microvascular dysfunction in patients with malignant hypertensionAlena Shantsila, Girish Dwivedi, Eduard Shantsila, et al.
American Journal of Hypertension|September 20, 2008
Hypertension due to a renin-secreting juxtaglomerular cell tumorD Gareth Beevers, Madhavi B Maheshwari, Peter G Ryan, et al.
Journal of the American College of Cardiology|July 21, 2004
Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Sunil K Nadar, Andrew D Blann, Sridhar Kamath, et al.
Hypertension (Dallas, Tex. : 1979)|July 10, 2002
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Charles G C Spencer, David Gurney, Andrew D Blann, et al.
Hypertension (Dallas, Tex. : 1979)|March 8, 2003
Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatmentDirk C Felmeden, Charles G C Spencer, Andrew D Blann, et al.
Chest|November 14, 2007
Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in hypertensionChristopher J Boos, Deirdre A Lane, Manas Karpha, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 12, 2011
Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factorV J Karthikeyan, Andrew D Blann, Sabah Baghdadi, et al.
Journal of Hypertension|December 2, 2010
Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnanciesVellore J Karthikeyan, Robin E Ferner, Sabah Baghdadi, et al.
American Journal of Hypertension|September 15, 2004
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Muzahir H Tayebjee, Sunil Nadar, Andrew D Blann, et al.
Pageof 5